Target Species:
Cattle
Indications for use:
For the treatment and prevention of bovine babesiosis (Redwater fever - Babesia divergens infection) only.
Contraindications:
* Imizol must not be administered intravenously or intramuscularly.
* Repeat doses of Imizol must not be given.
Special warnings for each target species:
Not for use in any other species.
Special precautions for use:
Estimate body weight carefully and do not exceed the recommended dosage.
Operator warnings:
Do not use if under medical advice not to work with compounds which may exhibit anti-cholinesterase activity.
Wash splashes of the product off the skin and eyes immediately. Wear suitable protective clothing (ie impermeable gloves) when using the product.
Seek medical advice immediately if adverse signs indicative of anti-cholinesterase activity are experienced by operators.
Adverse Reactions:
Animals may show cholinergic signs after dosing. It may be possible to alleviate these side effects by treatment with atropine sulphate.
While side-effects (salivation, discomfort, muscle tremors, tachycardia, cough, colics) are rare, they do occur and deaths from anaphylactoid reactions have been recorded following product use.
Use during pregnancy or lactation:
Treatment of pregnant animals has demonstrated that although the compound does cross the placental barrier there does not appear to be an adverse effect on the foetus or calf.
Interactions:
None known
Amounts to be administered and administration route:
The product is for subcutaneous injection administration only. The recommended dose regimen is as follows:
Indication | Dose |
Therapy (Treatment) | 1.0 ml/100 kg body weight (0.85 mg imidocarb/kg bw) |
Prevention* | 2.5 ml/100 kg body weight (2.125 mg imidocarb/kg bw) |
* For therapy of in-contact animals known to be exposed to an infection.
The product should be administered on a single occasion only. Do not administer by the intramuscular or intravenous route. Do not inject more than 10 ml per injection site.
Overdose:
At about 1.75x overdose of the recommended dose signs consistent with cholinergic activity started to manifest themselves.
Death can result at doses of 5x the recommended therapeutic dose or greater.
Withdrawal periods:
Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after a period of at least 213 days from treatment.
Milk for human consumption must not be taken during treatment. Milk must not be taken for human consumption from cattle until after at least 21 days from treatment.